Visual Impairment News and Research

Latest Visual Impairment News and Research

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).

26 Feb 2014

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for use within the National Health Service Scotland under a simple patient access scheme.

10 Feb 2014

Moderate aerobic exercise helps preserve nerve cells in retina after damage

Moderate aerobic exercise helps to preserve the structure and function of nerve cells in the retina after damage, according to an animal study appearing February 12 in The Journal of Neuroscience. The findings suggest exercise may be able to slow the progression of retinal degenerative diseases.

9 Feb 2014

Study: Probability of blindness due to glaucoma has decreased by nearly half

The probability of blindness due to the serious eye disease glaucoma has decreased by nearly half since 1980, according to a study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers speculate that advances in diagnosis and therapy are likely causes for the decrease, but caution that a significant proportion of patients still progress to blindness.

21 Jan 2014

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients.

16 Jan 2014

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients. With this new knowledge, investigators aim to accelerate the process of healing and repair in damaged corneas to ultimately reverse the effects of diabetes-induced eye complications.

15 Jan 2014

No added benefit from aflibercept, shows study

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein.

8 Jan 2014

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.

6 Jan 2014

People with diabetes at risk of developing diabetic macular edema during their lifetime

Despite recent advances in prevention and treatment of most vision loss attributed to diabetes, a new study shows that fewer than half of Americans with damage to their eyes from diabetes are aware of the link between the disease and visual impairment, and only six in 10 had their eyes fully examined in the year leading up to the study.

20 Dec 2013

Researchers investigate several non-invasive methods for measuring intracranial pressure

Do you ever turn your world upside down by standing on your head? After a few minutes you might feel some pressure in your face and around your skull. This is because headstands invert the body's blood flow, pushing more blood toward your head.

19 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Exposure to high-powered blue handheld laser devices can cause serious eye injuries

Exposure for even fractions of a second to high-powered blue handheld laser devices can cause serious eye injuries, according to a study recently released online in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers have concluded that the wide availability of these devices, which are often marketed as toys, could lead to an epidemic of ocular injuries, and greater public awareness and government intervention should be encouraged.

6 Dec 2013

Study finds way to regulate sleep patterns of children with brain disorders

For parents of children with brain disorders or visual impairment, nights can be long and frustrating, leading to even more difficult days as exhaustion takes hold.

29 Nov 2013

Auditory processing disorder diagnosis: an interview with Dr Doris-Eva Bamiou, UCL Ear Institute

It is a listening or hearing disorder, which is due to the brain’s defective analysis of sounds, so that individuals who are affected with this disorder cannot make sense of what they hear.

26 Nov 2013

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has received approval for the treatment of Macular Edema Following Central Retinal Vein Occlusion from the Japanese Ministry of Health, Labour and Welfare.

22 Nov 2013

Nurse educator receives 2013 ARN Educator Role Award at 39th Annual ARN Educational Conference

The Association of Rehabilitation Nurses (ARN) presented Brenda French, MSN CRRN VHA-CM, with the 2013 ARN Educator Role Award. French received her award at the 39th Annual ARN Educational Conference, held October 2-5 in Charlotte, NC.

13 Nov 2013

Black women with vitamin D deficiency during pregnancy more likely to deliver preterm babies

African-American and Puerto Rican women who have low levels of vitamin D during pregnancy are more likely to go into labor early and give birth to preterm babies, research led by the University of Pittsburgh Graduate School of Public Health reveals.

31 Oct 2013

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron Pharmaceuticals, Inc. today announced positive topline results for EYLEA® (aflibercept) Injection from the Phase 3 VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO).

21 Oct 2013

ADAGES III study receives NIH grant to elucidate genetics of glaucoma in African descents

A study led by Robert N. Weinreb, chairman and Distinguished Professor of Ophthalmology at the University of California, San Diego School of Medicine, has received a $6.4 million, 5-year grant from the National Eye Institute, part of the National Institutes of Health, to elucidate the genetics of glaucoma in persons of African descent.

12 Oct 2013

Retinitis pigmentosa test identifies mutation found in Ashkenazi Jewish population

You might not think to look to a urine test to diagnose an eye disease. But a new Duke University study says it can link what is in a patient's urine to gene mutations that cause retinitis pigmentosa, or RP, an inherited, degenerative disease that results in severe vision impairment and often blindness. The findings appear online in the Journal of Lipid Research.

9 Oct 2013

Visual Impairment News and Research

Latest Visual Impairment News and Research

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

Moderate aerobic exercise helps preserve nerve cells in retina after damage

Study: Probability of blindness due to glaucoma has decreased by nearly half

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

No added benefit from aflibercept, shows study

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

People with diabetes at risk of developing diabetic macular edema during their lifetime

Researchers investigate several non-invasive methods for measuring intracranial pressure

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Exposure to high-powered blue handheld laser devices can cause serious eye injuries

Study finds way to regulate sleep patterns of children with brain disorders

Auditory processing disorder diagnosis: an interview with Dr Doris-Eva Bamiou, UCL Ear Institute

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Nurse educator receives 2013 ARN Educator Role Award at 39th Annual ARN Educational Conference

Black women with vitamin D deficiency during pregnancy more likely to deliver preterm babies

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

ADAGES III study receives NIH grant to elucidate genetics of glaucoma in African descents

Retinitis pigmentosa test identifies mutation found in Ashkenazi Jewish population

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Visual Impairment News and Research

Latest Visual Impairment News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in